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Abstract
Genetic variations in human leukocyte antigens (HLA) are critical in host responses to infections, transplantation, and
immunological diseases. We previously identified associations with non-Hodgkin lymphoma (NHL) and the HLA-DRB1*01:01
allele and extended ancestral haplotype (AH) 8.1 (HLA-A*01-B*08-DR*03-TNF-308A). To illuminate how HLA alleles and
haplotypes may influence NHL etiology, we examined potential interactions between HLA-DRB1*01:01 and AH 8.1, and a
wide range of NHL risk factors among 685 NHL cases and 646 controls from a United States population-based case-control
study. We calculated odds ratios and 95% confidence intervals by HLA allele or haplotype status, adjusted for sex, age, race
and study center for NHL and two major subtypes using polychotomous unconditional logistic regression models. The
previously reported elevation in NHL risk associated with exposures to termite treatment and polychlorinated biphenyls
were restricted to individuals who did not possess HLA-DRB1*01:01. Previous associations for NHL and DLBCL with decreased
sun exposure, higher BMI, and autoimmune conditions were statistically significant only among those with AH 8.1, and null
among those without AH 8.1. Our results suggest that NHL risk factors vary in their association based on HLA-DRB1*01:01
and AH 8.1 status. Our results further suggest that certain NHL risk factors may act through a common mechanism to alter
NHL risk. Finally, control participants with either HLA-DRB1*01:01 or AH 8.1 reported having a family history of NHL twice as
likely as those who did not have either allele or haplotype, providing the first empirical evidence that HLA associations may
explain some of the well-established relationship between family history and NHL risk.
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Introduction
Human leukocyte antigens (HLA) are among the most
polymorphic genes in humans and result in variations of the
peptide-binding cleft, influencing the antigens bound and
presented to T cells [1]. In general, HLA Class I molecules
(HLA-A, -B, and -C) present foreign antigens to CD8+ cytotoxic T
lymphocytes (CTL), and HLA Class II molecules (HLA-DR,- DQ,
and -DP) present antigenic peptides to CD4+ T helper cells [2].
HLA play critical roles in human immunological diseases,
transplantation, and host defense against infections including
progression to the acquired immunodeficiency syndrome [3], all
known risk factors for non-Hodgkin lymphoma (NHL).
We previously conducted HLA Class I (A, B, C) and Class II
(DR) genotyping in a population-based multi-center case-control
study of NHL in the United States (U.S.). We reported HLA-
DRB1*01:01 as a novel susceptibility allele in NHL risk [4],
particularly for the follicular lymphoma subtype, which was
consistent with results from a genome-wide association study [4].
We also previously reported the association between the pro-
inflammatory cytokine, tumor necrosis factor (TNF) G-308A
promoter polymorphism with NHL and specifically with diffuse
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9Table 1. Risk factor distribution (demographics and family/medical history) by HLA-DRB1*01:01 and AH 8.1 (HLA-A*01-B*08-DR*03-
TNF-308A) among controls in the NCI-SEER NHL multicenter case-control study (adjusted for age, education, sex, race, study
center).
HLA-DRB1*0101 AH 8.1
Absent Present OR (95% CI) Absent Present OR (95% CI)
Select demographics
Sex
Male 283 49 1.00 (reference) 278 38 1.00 (reference)
Female 233 48 1.11 (0.71–1.774) 235 28 0.83 (0.49–1.41)
Race
White 442 89 1.00 (reference) 442 62 1.00 (reference)
Other/Unknown 74 8 0.52 (0.22–1.19) 71 4 NC
Age (y)
,45 80 14 1.00 (reference) 79 9 1.00 (reference)
45–64 220 35 0.88 (0.44–1.73) 213 32 1.32 (0.60–2.92)
$65 216 48 1.12 (0.57–2.19) 221 25 0.88 (0.38–2.02)
P-trend
Education (years)
,12 49 8 1.00 (reference) 45 7 1.00 (reference)
12–15 308 63 1.44 (0.63–3.29) 317 39 0.77 (0.32–1.88)
.15 159 26 1.19 (0.49–2.90) 151 20 0.69 (0.26–1.81)
P-trend
Study site
Seattle 172 27 1.00 (reference) 159 27 1.00 (reference)
Detroit 54 17 2.29 (1.13–4.66) 58 8 0.92 (0.38–2.23)
Iowa 181 38 1.23 (0.71–2.14) 186 24 0.75 (0.41–1.37)
Los Angeles 109 15 1.04 (0.51–2.12) 110 7 0.44 (0.18–1.08)
Family and medical history
Family history of NHL
No 482 87 1.00 (reference) 481 57 1.00 (reference)
Yes 14 8 2.81 (1.12–7.05) 16 5 2.35 (0.81–6.82)
Autoimmune conditions
No 487 95 1.00 (reference) 489 61 1.00 (reference)
Yes 29 2 NC 24 5 1.62 (0.58–4.50)
Asthma
No 245 40 1.00 (reference) 233 33 1.00 (reference)
Yes 34 5 0.88 (0.31–2.5) 31 6 1.27 (0.46–3.52)
Allergy
No 95 19 1.00 (reference) 97 14 1.00 (reference)
Yes 139 32 1.29 (0.67–2.47) 148 13 0.50 (0.20–1.22)
Surgeries (total number)
0–6 47 7 1.00 (reference) 45 5 1.00 (reference)
$7 232 38 0.72 (0.28–1.87) 219 34 1.44 (0.48–4.30)
Transfusion
No 408 86 1.00 (reference) 412 56 1.00 (reference)
Yes 100 11 0.44 (0.22–0.88) 95 9 0.69 (0.32–1.48)
Birth order
First/Middle 168 25 1.00 (reference) 158 22 1.00 (reference)
Last 48 12 1.75 (0.79–3.89) 49 9 0.98 (0.39–2.42)
Abbreviations: AH 8.1: ancestral haplotype 8.1 (HLA-A*01-B*08-DR*03-TNF-308A); HLA: human leukocyte antigen; NC:not calculated due to n,5 in cell; NCI-SEER:
National Cancer Institute Surveillance, Epidemiology & End Results; TNF: tumor necrosis factor.
doi:10.1371/journal.pone.0026949.t001
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e26949Table 2. Risk factor distribution (anthropometrics, sunlight and environmental exposures) by HLA-DRB1*01:01 and AH 8.1 (HLA-
A*01-B*08-DR*03-TNF-308A) among controls in the NCI-SEER NHL multicenter case-control study (adjusted for age, education, sex,
race, study center).
HLA-DRB1*0101 AH 8.1
Absent Present OR (95% CI) Absent Present OR (95% CI)
Anthropometrics and diet
BMI (kg/m2)
,25 151 30 1.00 (reference) 151 20 1.00 (reference)
25 to ,35 290 55 0.93 (0.56–1.54) 288 39 1.03 (0.57–1.85)
$35 45 6 0.65 (0.25–1.69) 42 4 NC
P-trend 0.44 0.7
Height (inches)
,65 123 27 1.00 (reference) 128 13 1.00 (reference)
65–70 250 38 0.79 (0.42–1.47) 237 31 1.43 (0.66–3.08)
$71 118 26 1.24 (0.54–2.90) 120 19 1.90 (0.70–5.18)
P-trend 0.6 0.2
Smoking status
Never 95 22 1.00 (reference) 99 11 1.00 (reference)
Ever 118 26 1.01 (0.52–1.96) 125 14 0.98 (0.42–2.31)
Ethanol (grams/week)
,1 86 18 1.00 (reference) 93 7 1.00 (reference)
$1 121 28 1.40 (0.67–2.92) 122 18 2.54 (0.98–6.59)
Vitamin B6 (milligrams)
,0.97 105 19 1.00 (reference) 101 17 1.00 (reference)
$0.97 102 27 1.50 (0.75–3.00) 114 8 0.39 (0.16–0.97)
Sunlight
Sun in teens (hours/week)
$14 170 41 1.00 (reference) 183 18 1.00 (reference)
,14 61 10 0.57 (0.26–1.26) 59 9 1.54 (0.63–3.81)
Sun in past 10 years (hours/week)
$14 85 29 1.00 (reference) 103 7 1.00 (reference)
,14 147 21 0.37 (0.18–0.75) 139 20 2.25 (0.85–5.91)
Eye color
Brown 73 16 1.00 (reference) 77 7 1.00 (reference)
Hazel 41 9 1.02 (0.39–2.64) 44 5 1.40 (0.41–4.76)
Green/blue 120 26 0.97 (0.46–2.06) 124 15 1.36 (0.53–3.53)
P-trend 0.98 0.6
Environmental exposures
Termite treatment ,1988
Not treated ,1988 364 75 1.00 (reference) 366 48 1.00 (reference)
None or DK 76 8 0.55 (0.25–1.23) 72 9 1.06 (0.48–2.34)
$1 76 14 1.08 (0.55–2.11) 75 9 1.19 (0.53–2.66)
P-trend 0.80 0.70
alpha-Chlordane (dust; ng/g)
,60.3 210 47 1.00 (reference) 210 31 1.00 (reference)
60.3–5,870 59 5 0.39 (0.14–1.06) 56 3 NC
PCB180 (dust; ng/g)
0–20.7 208 40 1.00 (reference) 211 23 1.00 (reference)
.20.7 61 12 1.02 (0.49–2.16) 55 11 1.93 (0.82–4.41)
PCB180 (blood; ng/g)
#28.7 21 3 1.00 (reference) 19 4 1.00 (reference)
.28.7 56 11 NC 58 8 NC
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large consortial efforts [6,7]. Although we previously evaluated the
joint effects between TNF G-308A and NHL risk factors [8], we
have since demonstrated that the ancestral haplotype 8.1 (AH 8.1:
HLA-A*01-B*08-DR*03-TNFG-308A) whereby HLA alleles are in
linkage disequilibrium with TNF, is associated with DLBCL [9].
Notably, all individuals with the HLA-A*01-B*08-DR*03 haplo-
type also have the variant TNF G-308A polymorphism in our
population [9]. Because previous investigations have demonstrated
elevated TNF-alpha expression among healthy individuals with
AH 8.1, it is plausible that the AH 8.1 reflects a more accurate
downstream phenotype, reflecting a synergistic relationship
between TNF and HLA and chronic inflammatory status that
would result in elevated DLBCL risk [10]. On the other hand,
possession of HLA-DRB1*01:01 likely confers a different pheno-
type as it is associated with rheumatoid arthritis and may reflect
propensity for generating autoantibodies.
Confirmed risk factors for NHL include autoimmune conditions
[11], certain infectious agents [12], and family history of
lymphoma [13]. Suggestive associations also include increased
NHL risk with smoking [14], obesity [15], and decreased NHL
risk with alcohol intake [16] and sunlight [17]. A growing body of
evidence also implicates organochlorine pesticides in NHL risk
[18,19]. Evidence for decreased NHL risk with atopic conditions
(e.g., allergies and asthma) and vitamin B6, height, and later birth
order has also been reported, but these associations require further
replication [20].
To illuminate how HLA alleles and haplotypes may influence
NHL etiology, we explored potential interactions between
implicated HLA alleles and haplotypes, specifically HLA-
DRB1*01:01 and AH 8.1, and NHL risk factors. Each of the risk
factors has previously been independently evaluated and we
include those for which associations consistent to the current body
of literature were found [8]. Because the major subtypes of NHL
differ in their pattern of some risk factors, we also examined the
distinctive effects on the two major NHL subtypes, DLBCL and
follicular lymphoma.
Materials and Methods
Study population
Details have been described elsewhere [5]. In brief, the multi-
center National Cancer Institute – Surveillance, Epidemiology
and End Results (NCI-SEER) NHL case-control study popula-
tion comprised 1,321 NHL cases identified in four SEER
registries (Iowa; Detroit, MI; Los Angeles, CA; Seattle, WA)
aged 20–74 years and newly diagnosed between July 1998–June
2000 [5]. Cases were not known to have HIV infection. 1,057
population controls were identified by random digit dialing (,65
years) and from Medicare eligibility files ($65 years). The
response rate for cases was 59% and 44% for controls. Written
informed consent was obtained from each participant prior to
interview. All study participants were asked to provide a venous
blood or mouthwash buccal cell sample. The present analysis was
conducted on study participants who provided blood and for
whom HLA typing was completed (685 cases, 646 controls).
Results were nearly identical when we restricted the analysis to
the 610 cases and 555 controls who self-reported to be non-
Hispanic Caucasians and from whom sufficient DNA were
available for HLA allelotyping [4,9]. Because no association was
observed between genotype and race or between race and risk
factors evaluated, we present results for all participants to
maximize our sample size and power for evaluation of
interactions. This study was approved by the following institu-
tional review boards: the Institutional Review Board of the NCI
(NCI); the Health Sciences Institutional Review Board (USC); the
Human Subjects Division Institutional Review Board (UW); the
Fred Hutchinson Cancer Research Center Institutional Review
Board (FHCRC); the Wayne State University Division of
Research Institutional Review Road (Wayne State); and the
University of Iowa Institutional Review Board (Iowa). Written
consent was obtained from all participants included in the study.
Histopathology
Pathology information was derived from abstracted reports by
the local diagnosing pathologist. All cases were histologically
confirmed and coded according to the International Classification
of Diseases for Oncology (ICD), 2
nd Edition [21] and updated to
the WHO/ICD-O-3. We evaluated risk for NHL and two major
histologic subtypes: DLBCL (ICD-O-2: 9680-84, 9688) and
follicular lymphoma (9690-91, 9695-98).
Laboratory methods
As previously described, DNA was extracted using Puregene
Autopure DNA extraction kits (Gentra Systems, Minneapolis,
MN) [5]. Four-digit HLA Class I (A, B, C) and Class II genotyping
(DRB1) was conducted at NCI-Frederick (Frederick, MD)
according to sequence-specific oligonucleotide probe (SSOP)
hybridization and sequence-based typing protocols developed by
the 13
th International Histocompatibility Workshop [22]. HLA
alleles were defined as presence or absence of the specific allele.
TNF genotyping was conducted at the National Cancer Institute
Core Genotyping Facility (Gaithersburg, MD, USA) using the
Taqman (Foster City, CA, USA) platform. TNF G-308A was
defined by genotype (GG (referent), GA and AA) [5]. HLA
haplotypes were determined using ‘FastHap’, which determines
haplotypes by expectation maximization (http://home.ncifcrf.
gov/ccr/lgd/bioinformatics/index_n.asp) [9]. Agreement for
quality control duplicates (n=100) was more than 99%.
HLA-DRB1*0101 AH 8.1
Absent Present OR (95% CI) Absent Present OR (95% CI)
Total furans (blood; mol/g)
#0.057 19 1 1.00 (reference) 19 1 1.00 (reference)
.0.057 58 13 NC 58 11 NC
Abbreviations: AH 8.1: ancestral haplotype 8.1 (HLA-A*01-B*08-DR*03-TNF-308A); HLA: human leukocyte antigen; NC:not calculated due to n,5 in cell; NCI-SEER:
National Cancer Institute Surveillance, Epidemiology & End Results; TNF: tumor necrosis factor.
doi:10.1371/journal.pone.0026949.t002
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e26949Questionnaire Risk Factor Data
Methods and details of data collection were previously described
[8] and risk factors were categorized as previously reported [8]. All
study participants were queried on: (i) family history defined as any
first-degree family member having NHL or lymphoma not
otherwise specified (yes, no); (ii) history of immune-related
disorders (Sjogren’s syndrome, lupus, Crohn’s disease, ulcerative
colitis, rheumatic heart disease, polymyalgia rheumatica, sarcoid-
osis, multiple sclerosis, uveitis, myasthenia gravis, polymyositis,
dermatomyositis, and/or celiac disease) (yes, no); (iii) blood
transfusions (yes, no); (iv) number of surgeries since birth (0–6,
$7); (v) birth order (first/middle-born child, last born); (vi) height
(,65, 65–70,71+ inches); (vii) body mass index (BMI) as weight
(kg) divided by height (m) squared (,25, 252,35, 35+ kg/m2);
(viii) termite treatment via a detailed history of pesticide use in
each residence occupied for at least 2 years since 1970 and
whether the termite treatments occurred before or after 1988
when the termiticide chlordane was banned in the United States.
To accommodate a large number of questions during the
interview, we used a split-sample questionnaire design, with the
core questions above queried for all respondents and additional
questions for either group A (all black and 50% of non-black
participants) or group B (50% of non-black participants).
Additional questions included those on: (ix) asthma (yes, no) ; (x)
vitamin B6 intake, dichomotomized by the median intake among
controls (,0.97, $0.97 mg); (xi) smoking status (never, ever); (xii)
alcohol intake (,1, $1 grams/week); (xiii) sunlight in teens and
past 10 years (,14, $14 hours/week); eye color (brown, hazel,
green/blue); and (xiv) hay fever and other allergies, excluding food
allergies (yes, no). We note that for the each of the exposures
queried as part of the split-sample, we have systematically
compared the subgroup of participants to the overall population
and have found them to be comparable [8].
Biospecimen-based exposures. alpha-Chlordane and
PCB180 were measured from a subset of cases and controls
from whom dust samples were collected and analyzed (682 cases,
513 controls) [18,19,23] (alpha-chlordane: ,60.3, 60.3–5,870 ng/
g; PCB180 (0–20.7; .20.7 ng/g). PCB180 and total furans were
evaluated in plasma samples in a subset of 100 untreated cases and
100 controls [23]: PCB180 (#28.7 , .28.7 ng/g lipid), total furans
(#0.057, .0.057 pg/g lipid).
Statistical Analysis
Independence of risk factors. Among controls, we
calculated odds ratios (OR) and 95% confidence intervals (95%
CI) for each risk factor with the dichotomized genotype,
comparing the presence of a variant allele or haplotype with the
absence of the allele or haplotype (Tables 1 and 2) using
unconditional logistic regression. For ordinal risk factors with at
least three values, we calculated the P-trend for a linear model.
Effects of risk factors by genotype and p-interaction. For
all NHL cases and for DLBCL and follicular lymphoma, we
calculated OR and 95% CI for each risk factor using multivariable
polychotomous unconditional logistic regression for case-control
comparisons. In general, we chose as the reference group the
category carrying the lowest NHL risk. To determine the p-
interaction, we conducted the Wald Chi-square test for homo-
geneity of the associations with risk factors by genotype strata. All
analyses were conducted using SAS 9.2 (SAS Institute).
Although we calculated p-interaction, we evaluated our results
based on comparison to previously known and demonstrated risk
factors associations for NHL. Because statistically significant p-
interactions can be generated based on risk estimates that go in
different directions, our criteria for identifying notable results was
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associations were observed and restricted to a specific HLA allele
or genotype and null in the other allele or genotype, even if the p-
interaction was not statistically significant.
Results
Associations among controls (Tables 1 and 2)
Among control participants, there was a two-fold association
between those with either HLA-DRB1*01:01 or AH 8.1 and
reporting having a family history of NHL, compared to those who
did not have either allele or haplotype. The risk estimates for
family history of NHL were generally similar but statistically
significant for HLA-DRB1*01:01 (OR=2.81, 95% CI=1.12–7.05)
but not AH 8.1 (OR=2.35, 95% CI=0.81–6.82). Transfusion
history was inversely associated with both HLA-DRB1*01:01
(OR=0.44, 95% CI=0.22–0.88) and AH 8.1 (OR=0.69, 95%
CI=0.32–1.48). Other risk factor associations among controls
included vitamin B6 intake with AH 8.1 only and sun in past 10
years with HLA-DRB1*01:01 only. No other risk factors were
associated with either HLA-DRB1*01:01 or AH 8.1.
Effects stratified by HLA-DRB1*01:01 (Tables 3 and 4)
For NHL, statistically significant interactions (p=0.02) were
observed between HLA-DRB1*01:01 and termite treatment before
1988 and blood-based exposures to PCB180 whereby previously
reported 1.5-fold elevation in NHL risk for these environmental
exposures were limited and statistically significantly only among
individuals who did not have the HLA-DRB1*01:01 allele. There
were no statistically significant interactions specific to DLBCL or
follicular lymphoma, though sample size was limited.
Effects stratified by AH 8.1 (Tables 5 and 6)
We observed statistically significant interactions (p=0.03) for
NHL risk between sun exposure in the past 10 years, eye color and
AH 8.1, where the previously reported two-fold NHL risk increase
associated with lower sun exposure was restricted to and
statistically significant only for individuals with the AH 8.1. The
interaction (but not the risk estimate) between exposure to sun in
the past 10 years remained statistically significant (p=0.04) for
DLBCL. The association between sun exposure in the past 10
years and NHL and DLBCL among individuals without the AH 8.1
was null.
The previously reported risk associations between autoimmune
conditions and BMI with DLBCL and between height and alpha-
chlordane exposure with NHL were all statistically significant only
among those with AH 8.1. Additionally, an association between
self-reported allergies and NHL was also statistically significant
only among those with AH 8.1. Among those without AH 8.1,
associations for these NHL risk factors were null. There were no
statistically significant interactions for follicular lymphoma.
Discussion
This exploratory evaluation of gene-environment interactions
for a broad spectrum of NHL risk factors with implicated NHL
risk loci, HLA-DRB1*01:01 and AH 8.1, suggests that environ-
mental exposures may interact with HLA-DRB1*01:01 and sun-
related exposures with AH 8.1 in altering NHL risk. Additionally,
previously reported effects for autoimmune conditions and BMI
with DLBCL also appeared restricted among those with AH 8.1.
For sufficient power to confirm these observations, especially by
NHL subtype, large consortial efforts will be required. Our
observation that both HLA-DRB1*01:01 and AH 8.1 are
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participants offers the first evidence that HLA associations may
explain some of the well-established relationship between family
history and NHL risk [13]. Although this association may seem
like an obvious one, our data provide the first empirical evidence
for this association and, importantly, previously implicated single
nucleotide polymorphisms (e.g., TNF and interleukin 10) with
NHL have not in fact been shown to be associated with family
history of NHL. Other associations between HLA-DRB1*01:01
and AH 8.1 with NHL risk factors among our control population
with transfusion history, vitamin B6 intake and sun exposure,
support the need for further research in delineating the
interrelatedness versus independence of gene and environmental
risk factors in understanding lymphoma etiology.
Confirming these potential interactions between NHL risk
factors with HLA-DRB1*01:01 and AH 8.1 offers important clues
regarding potential mechanisms of action for the implicated risk
factors. Interaction with HLA-DRB1*01:01 would implicate
autoantibody production in triggering responses to antigens. On
the other hand, AH 8.1 is thought to reflect synergistic effects
between TNF and HLA which induces elevated TNF expression
and inflammatory responses. Our results thus suggest that NHL
risk factors that interact with AH 8.1 (e.g., sun exposure and BMI)
might involve inflammatory mechanisms. Recreational sun
exposure has been linked to decreased NHL risk in a number of
studies and pooled analysis of case-control studies [17], but the
mechanism behind this association is presently unknown and
proposed mechanisms such as benefits from vitamin D have not
been consistently supported in cohort studies [24]. Our previous
analyses of gene-environment interactions and sun exposure did
not reveal interactions with two candidate immune genes (TNF
and IRF4) [25,26] but our results here, which demonstrate
interaction between AH 8.1 with sun exposure support the
hypothesis that sun exposure may modulate NHL risk through
altered immunity and inflammation. In addition, components of
the AH 8.1, such as HLA-B*08, are associated with a number of
autoimmune conditions and NHL risk factors, including systemic
lupus erythematosis and Sjogren syndrome. Further investigation
of potentially common mechanisms between these risk factors with
NHL is thus warranted.
Study strengths include our systematic approach to evaluating
the joint effects of two important gene variations with a wide range
of NHL risk factors observed in the present study that have been
replicated in large pooled analyses or are consistent with the
literature [8]. Study limitations include the small sample sizes for
some analyses that resulted from the split-sample design of the
parent study, decreasing our statistical power to detect significant
interactions, particularly within subtypes. In our data interpreta-
tion, we assessed previously reported associations to determine
whether these known associations were consistent by HLA
DRB1*01:01 or AH 8.1 status, or if they were restricted and
statistically significant by genotype or haplotype strata. Although
we present p-interactions, we did not place sole emphasis on this
statistic as they could easily be influenced by risk estimates that
lean in opposite directions. Finally, we acknowledge that we may
have failed to detect true interactions due to limited statistical
power, imperfect measures of exposures and of genes, particularly
as not all cis-SNPs necessarily effect local genes and we cannot rule
out effects from a trans gene.
Our results require replication in a large independent or pooled
effort, such as within the InterLymph Consortium, and among
prospective studies. In the emerging view of complex etiologies for
NHL with potentially multiple paths to lymphomagenesis, HLA
associations with NHL may explain a portion of the reported
associations between family history and NHL risk. If confirmed in
independent data, they provide important evidence that NHL risk
factors, including environmental exposures to organochlorines,
sun exposure/pigmentation, autoimmune conditions, and BMI,
may vary according to a person’s HLA-DRB1*01:01 or AH 8.1
status.
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